Interact with experts and peers.

Recent Posts

10 of 47 Shown
  • NRTI-Sparing Regimens: The Search Goes On

    Joel E. Gallant MD, MPH - 4/14/2014
    Although we don’t yet have a perfect NRTI-sparing regimen, here I describe the circumstances when I do use one and the agents I select.
  • Minimizing Bone Loss in Patients Starting ART: As Simple As D/Ca?

    Andrew R. Zolopa MD - 4/14/2014
    Following CROI, I now intend to test for vitamin D deficiency in all my patients who are starting ART. Here’s why.
  • Recent STI: A Predictor of HIV Acquisition?

    Jeanne Marrazzo MD, MPH - 9/6/2013 2 comments / Last Comment: 12/17/2013
    Jeanne Marrazzo, MD, MPH, has disclosed that she has received funds for research support from Cepheid, Medicis, and MethylGene.
  • Is It OK to Switch Patients to the Elvitegravir Single-Tablet Regimen?

    Andrew R. Zolopa MD - 8/19/2013 2 comments / Last Comment: 10/8/2013
    Until we have data from switch studies, should we hold off from switching patients to the coformulation of tenofovir/emtricitabine/elvitegravir/cobicistat?
  • Managing HIV/HCV Coinfection: Treat or Wait?

    Renslow Sherer MD - 8/15/2013 2 comments / Last Comment: 3/3/2014
    How should we counsel patients with moderate fibrosis on whether they should start a current HCV regimen or wait for newer regimens to be available?
  • ART and Cardiovascular Risk: How I Managed a Patient With New Onset Unstable Angina

    Renslow Sherer MD - 8/13/2013 3 comments / Last Comment: 10/8/2013
    How should an HIV clinician respond when a patient with undetectable viral load progresses from having a risk of cardiovascular disease to established ischemic heart disease?
  • New WHO Guidelines: Ethical Dilemmas in Treating Earlier With Suboptimal Strategies

    Joel E. Gallant MD, MPH - 7/29/2013 4 comments / Last Comment: 8/29/2013
    Would it be a mistake to start treating earlier in resource-constrained settings before addressing the greater challenge of treating with safer drugs and better monitoring?
  • Screening for Anal Dysplasia: Where Do We Start and Where Should We Go?

    Joseph J. Eron, Jr. MD - 7/10/2013 2 comments / Last Comment: 4/1/2014
    There are currently no nationally accepted guidelines for screening HIV-positive patients for anal dysplasia. Which patients should we be screening?
  • Should I Screen My Treatment-Naive Patient for Integrase Inhibitor Resistance?

    Joseph J. Eron, Jr. MD - 7/5/2013 11 comments / Last Comment: 4/1/2014
    When exactly should you suspect integrase inhibitor resistance in a treatment-naive patient?
  • What Is the Most Common Cause of Hearing Loss Among People Living With HIV?

    Renslow Sherer MD - 7/1/2013
    A recent conference presentation provided important insights into the prevalence and clinical issues associated with this complication.
10 of 47 Shown
Show 10 More